Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The Chinese allergic asthma drug market is transitioning from traditional treatments to precision medicine, with a focus on monoclonal antibodies targeting various pathways such as IL-5 and IL-4Rα, indicating a shift towards individualized treatment strategies [4][6] - The market size for allergic asthma drugs in China is projected to grow from CNY 11.2 billion in 2018 to CNY 19.6 billion by 2024, with a compound annual growth rate (CAGR) of 9.8%. By 2030, the market is expected to reach CNY 46.7 billion, driven by an expanding patient population and increasing demand for innovative therapies [7][8] - The report highlights the emergence of local companies in the allergic asthma drug market, which are leveraging policy changes and technological advancements to challenge multinational corporations' dominance [17][18] Market Background - The report outlines that allergic asthma is primarily driven by Th2 cell-mediated immune mechanisms and is associated with other allergic conditions [5] - The market is evolving from a focus on inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA) to include biologics and targeted therapies, reflecting a significant transformation in treatment approaches [6] Market Status - The Chinese allergic asthma drug market is experiencing robust growth, with over 40 million patients and nearly one million new cases annually, leading to increased drug demand [7][8] - The report notes that the global allergic asthma patient population is expected to rise from 471.3 million in 2018 to 560.6 million by 2030, with China's growth slightly outpacing the global average [11][12] Market Competition - The competitive landscape is characterized by a mix of multinational corporations and local innovators, with companies like GSK and AstraZeneca maintaining significant market shares through established product lines and clinical data [16][17] - Local companies are capitalizing on the "patent cliff" effect and are making strides in the development of biosimilars and targeted therapies, thereby reshaping the competitive dynamics [17][18] Development Trends - The report identifies several key trends, including the acceleration of precision medicine and targeted therapies, the breakthrough of domestic inhalation formulations, and the integration of digital technologies in patient management [33][34][37] - The shift towards a multi-faceted market driven by policy reforms and the coexistence of innovative and cost-effective generic drugs is highlighted as a significant trend [36]